ducovest

INCY:NSD-Incyte Corporation (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 69.91

Change

0.00 (0.00)%

Market Cap

USD 13.52B

Volume

0.40M

Analyst Target

USD 106.20
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation

Company Website : https://www.incyte.com

Currency: USD

Country : USA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

 USD 120.60B
REGN Regeneron Pharmaceuticals Inc

N/A

 USD 84.94B
ARGX argenx NV ADR

N/A

 USD 36.54B
ALNY Alnylam Pharmaceuticals Inc

N/A

 USD 31.66B
BGNE BeiGene Ltd

N/A

 USD 20.24B
UTHR United Therapeutics Corporatio..

N/A

 USD 16.18B
MRNA Moderna Inc

N/A

 USD 16.10B
RPRX Royalty Pharma Plc

N/A

 USD 15.27B
SMMT Summit Therapeutics PLC

N/A

 USD 13.67B
INSM Insmed Inc

N/A

 USD 13.20B

ETFs Containing INCY

XDNA:CA iShares Genomics Immunolo.. 5.01 % 0.00 %

N/A

 CAD 5.33M
IDNA iShares Genomics Immunolo.. 4.93 % 0.00 %

N/A

 USD 0.12B
DXSI:XETRA Xtrackers - Stoxx Europe .. 4.65 % 0.00 %

N/A

 USD 0.02B
CURE:AU ETFS S&P Biotech ETF 2.63 % 0.00 %

N/A

 USD 0.04B
SAGP The Advisorsa Inner Circl.. 1.96 % 0.00 %

N/A

 USD 0.04B
LABU Direxion Daily S&P Biotec.. 1.95 % 1.14 %

N/A

 USD 0.82B
RSPH Invesco S&P 500 Equal Wei.. 1.92 % 0.00 %

N/A

 USD 0.88B
MRND 1.89 % 0.00 %

N/A

 N/A
ZUH:CA BMO Equal Weight US Healt.. 1.74 % 0.39 %

N/A

 CAD 0.23B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

N/A

 USD 3.54M
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

N/A

 N/A
GURU Global X Guru Index ETF 0.00 % 0.75 %

N/A

 N/A
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

N/A

 N/A
JSMD Janus Henderson Small/Mid.. 0.00 % 0.50 %

N/A

 USD 0.45B
UBIO 0.00 % 0.95 %

N/A

 N/A
ZBIO Zenas BioPharma, Inc. Com.. 0.00 % 0.95 %

N/A

 N/A
2B77:F iShares Ageing Population.. 0.00 % 0.00 %

N/A

 N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.34% 72% C 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.34% 72% C 64% D
Trailing 12 Months  
Capital Gain 11.53% 72% C 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.53% 72% C 65% D
Trailing 5 Years  
Capital Gain -20.91% 70% C- 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.91% 69% C- 35% F
Average Annual (5 Year Horizon)  
Capital Gain -8.81% 34% F 22% F
Dividend Return -8.81% 34% F 21% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 16.59% 97% N/A 81% B-
Risk Adjusted Return -53.10% 20% F 13% F
Market Capitalization 13.52B 98% N/A 94% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.